Osaic Holdings
BTAI

Osaic Holdings’s BioXcel Therapeutics BTAI Stock Holding History

Osaic Holdings’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.9K Hold
16,214
– – ﹤0.01% 6079
2026
Q1 		$21.7K Buy
16,214
+465
+3% +$766 ﹤0.01% 5799
2025
Q4 		$25.2K Buy
15,749
+666
+4% +$1.37K ﹤0.01% 5715
2025
Q3 		$61.1K Buy
15,083
+10,030
+198% +$31.6K ﹤0.01% 5185
2025
Q2 		$9.14K Buy
5,053
+3,169
+168% +$5.25K ﹤0.01% 6213
2025
Q1 		$3.82K Buy
1,884
+954
+103% +$3.56K ﹤0.01% 6313
2024
Q4 		$5.5K Buy
930
+399
+75% +$3.33K ﹤0.01% 6140
2024
Q3 		$5.18K Buy
531
+242
+84% +$3.25K ﹤0.01% 6174
2024
Q2 		$5.93K Buy
289
+218
+307% +$7.3K ﹤0.01% 6087
2024
Q1 		$3.19K Buy
71
+44
+163% +$2.1K ﹤0.01% 6292
2023
Q4 		$1.27K Buy
27
+8
+42% +$445 ﹤0.01% 6669
2023
Q3 		$759 Sell
19
-117
-86% -$11.8K ﹤0.01% 6904
2023
Q2 		$14.4K Buy
136
+25
+23% +$8.32K ﹤0.01% 5763
2023
Q1 		$33.1K Sell
111
-52
-32% -$22.2K ﹤0.01% 5248
2022
Q4 		$56K Sell
163
-15
-8% -$3.63K ﹤0.01% 4844
2022
Q3 		$34K Sell
178
-41
-19% -$9.52K ﹤0.01% 5194
2022
Q2 		$47K Sell
219
-24
-10% -$5.05K ﹤0.01% 5001
2022
Q1 		$94K Buy
243
+28
+13% +$8.12K ﹤0.01% 4638
2021
Q4 		$70K Sell
215
-743
-78% -$319K ﹤0.01% 4882
2021
Q3 		$465K Buy
958
+84
+10% +$36.9K ﹤0.01% 3104
2021
Q2 		$406K Buy
874
+255
+41% +$139K ﹤0.01% 3234
2021
Q1 		$428K Buy
619
+340
+122% +$274K ﹤0.01% 3038
2020
Q4 		$206K Buy
279
+63
+29% +$49.1K ﹤0.01% 3458
2020
Q3 		$152K Buy
216
+124
+135% +$93.1K ﹤0.01% 3490
2020
Q2 		$78K Sell
92
-22
-19% -$14.3K ﹤0.01% 3869
2020
Q1 		$39K Buy
+114
New +$41K ﹤0.01% 4158

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Osaic Holdings's BTAI Position: Q2 2026 in Review

Osaic Holdings held its BioXcel Therapeutics (BTAI) position steady in Q2 2026 at 16,214 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6079.

Osaic Holdings first reported a position in BTAI in Q1 2020 and has held it in 26 quarters since. The position peaked at $465K in Q3 2021. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Osaic Holdings held 16,214 shares of BioXcel Therapeutics worth $22.9K as of Q2 2026.
  • Osaic Holdings left its BioXcel Therapeutics share count unchanged in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #6079 holding.
  • Osaic Holdings first reported a position in BioXcel Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's BioXcel Therapeutics position peaked at $465K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.